Key Highlights

● Regulatory news drove sharp moves in both directions.

● A device clearance lifted one name.

● A European opinion and a delayed filing weighed on others.

● Financing was another theme.

Health care stocks offered a vivid reminder on Friday, November 13, 2026, that regulatory decisions can make or break a smaller company's share price in a single session. While the broader market was preoccupied with a chip-led selloff, several drug and device developers moved sharply on news from regulators or on changes to their own timelines.

The S&P 500 slipped 30.73 points to 7,561.67, and the Russell 2000, the small-cap benchmark where many biotechs live, dipped 8.57 points to 2,790.49.

The winners: clearances and approvals

Tandem Diabetes Care (NASDAQ:TNDM) jumped after the US Food and Drug Administration cleared a tubeless option for its Tandem Mobi insulin pump. The company plans a full US launch in the first half of 2027. As general context, tubeless designs are popular with many people living with diabetes because they remove the tubing that connects a traditional pump to the body, and a clearance can open the door to a broader set of customers.

In Europe, Novo Nordisk (NYSE:NVO) announced EU approval of FREHEMGO, also known as denecimig, for haemophilia A, according to market data. No price move tied to the news was confirmed.

SS Innovations (NASDAQ:SSII), which makes the SSi Mantra surgical robot, also rallied after naming a new president and chief financial officer, though the company is still answering FDA questions about the robot.

The setbacks: an opinion and a delay

On the other side of the ledger, Zevra Therapeutics (NASDAQ:ZVRA) slid after a committee of the European Medicines Agency, known as the CHMP, issued a negative opinion on arimoclomol. As general context, the CHMP's opinions feed into the European Commission's final decisions on drug approvals, so a negative view is typically seen as a significant hurdle for a product's path in Europe.

Candel Therapeutics (NASDAQ:CADL) tumbled after pushing its planned approval filing for a prostate cancer treatment to mid-2027. Investors in development-stage biotechs tend to react strongly to timeline changes, since a delay can push back potential Revenue and raise questions about funding needs.

Financing was the other theme

Not every big move was about regulators. Vir Biotechnology (NASDAQ:VIR) sank after pricing 15 million shares at $10.00 each, below its prior close of $12.12, to raise $150 million in gross proceeds. Prime Medicine (NASDAQ:PRME), by contrast, climbed after closing a share sale at $3.50 a share that raised $143.7 million in gross proceeds and extended its cash runway through 2027.

Elsewhere, Electra Therapeutics and SELLAS Life Sciences (NASDAQ:SLS) edged lower. SELLAS has said results from its REGAL study are expected this month.

As general context, many smaller biotech companies have no product revenue, so their value rests heavily on the odds that a drug or device reaches the market. Regulatory decisions, trial readouts and financing terms can each reshape those odds overnight, which is why the sector often sees outsized swings in both directions.

The macro backdrop adds another layer. With traders seeing a December Fed rate hike as near-certain and the 10-year Treasury Yield at its highest since October, funding conditions for cash-hungry developers remain a focus.

What to watch next for biotech stocks

Investors will watch Tandem's launch preparations for Mobi's tubeless option, Zevra's next steps in Europe and any update from Candel on its revised filing timeline. SELLAS's REGAL data are expected this month. More broadly, Fed minutes on Wednesday will shape the rate outlook that influences biotech financing.